(Press-News.org) As cannabis becomes more potent and widely used in the United States – especially among young adults – concerns about cannabis use disorder are growing. More than 16 million Americans meet the criteria, yet most never receive treatment.
Despite the scale of the issue, we know surprisingly little about who gets help and why so many don’t. This treatment gap raises urgent questions about access, awareness and stigma. As laws and attitudes around cannabis shift, understanding the real-world barriers to care is more important than ever.
A new study from Florida Atlantic University and collaborators is among the few to track cannabis use treatment trends over time, drawing on national data from the 2003, 2011 and 2019 National Survey on Drug Use and Health. Researchers analyzed 16 years of patterns, examining how factors like gender, race and ethnicity, age, education, insurance coverage, and urban versus rural residence influence access to treatment.
Using robust statistical methods, the study identifies key predictors of who receives help – and reveals the most common reasons why many don’t. The findings offer critical insights to guide more targeted, equitable approaches to addressing cannabis use disorder as legalization and usage rates continue to rise.
Results of the study, published in the journal Substance Use & Misuse, reveal a concerning trend: over the 16-year period, the number of individuals receiving treatment for cannabis use disorder declined, even as the need remained high – from 19% in 2003 to just 13% in 2019. Across all three time points – 2003, 2011 and 2019 – most people with cannabis use disorder did not receive any form of treatment.
When asked why they didn’t seek help, participants cited a range of barriers. Increasingly, individuals reported not knowing where to find treatment or feeling unready to stop using cannabis. Other common reasons included the cost of treatment, concerns about stigma, and fears that seeking help could negatively impact their job or career.
The study also identified consistent predictors of who was more likely to receive treatment. People who had received mental health services in the past year or who were under community supervision (such as probation or parole) were significantly more likely to access treatment for cannabis use disorder.
Interestingly, Hispanic individuals had much lower odds of receiving treatment compared to non-Hispanic white individuals in 2003, but this difference was no longer significant in more recent years – suggesting some progress toward equal access. Additionally, a prior arrest, which was not linked to treatment in 2003, became a strong predictor in later years, associated with two to three times higher odds of receiving cannabis use disorder treatment.
“Cannabis use disorder treatment is often overshadowed by treatments for other substance use disorders, despite its growing prevalence and impact,” said Brian D. Graves, Ph.D., senior author and an assistant professor in the Phyllis and Harvey Sandler School of Social Work within FAU’s College of Social Work and Criminal Justice. “Barriers to treatment are not only widespread but also evolving over time. Understanding these shifting challenges – and the consistent predictors of who does and doesn’t get help – can guide targeted efforts to expand access and improve outcomes for those struggling with this disorder.”
Most individuals with cannabis use disorder were male, and those who received treatment were more likely to be older, non-Hispanic white, and have lower incomes. Over time, fewer people with private insurance sought treatment, while more used public insurance.
Mental health care and involvement with the justice system were strong predictors of receiving treatment. People who had been arrested or were on probation or parole were much more likely to access care. Self-help groups and outpatient rehab were the most common treatment settings.
Key barriers to treatment included not feeling ready to stop, not knowing where to go, cost, stigma and fear of job-related consequences – concerns that increased in recent years. For example, in 2019, 38% didn’t know where to seek help, and 28% feared job impacts, up from single-digit percentages in earlier years.
“Our findings highlight an urgent and growing need for targeted outreach and improved education about available treatment options for cannabis use disorder,” said Graves. “Beyond simply increasing awareness, we must address the practical obstacles – like affordability and access – as well as the perceptual barriers such as stigma and misinformation that prevent many individuals from seeking help. Achieving access to care requires coordinated, systemic efforts that prioritize the unique challenges faced by varied communities affected by cannabis use disorder. Only through comprehensive strategies can we hope to close the treatment gap and provide effective support to those who need it most.”
Study co-authors are Orion Mowbray, Ph.D., University of Georgia; Lydia Aletraris, Ph.D., University of Georgia; and Jay O’Shields, Ph.D., University of Alabama at Birmingham.
- FAU -
About Florida Atlantic University:
Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, Florida Atlantic serves more than 30,000 undergraduate and graduate students across six campuses located along the Southeast Florida coast. In recent years, the University has doubled its research expenditures and outpaced its peers in student achievement rates. Through the coexistence of access and excellence, Florida Atlantic embodies an innovative model where traditional achievement gaps vanish. Florida Atlantic is designated as a Hispanic-serving institution, ranked as a top public university by U.S. News & World Report, and holds the designation of “R1: Very High Research Spending and Doctorate Production” by the Carnegie Classification of Institutions of Higher Education. Florida Atlantic shares this status with less than 5% of the nearly 4,000 universities in the United States. For more information, visit www.fau.edu.
END
Resonantly tunable quantum cascade lasers (QCLs) are high-performance laser light sources for a wide range of spectroscopy applications in the mid-infrared (MIR) range. Their high brilliance enables minimal measurement times for more precise and efficient characterization processes and can be used, for example, in chemical and pharmaceutical industries, medicine or security technology. Until now, however, the production of QCL modules has been relatively complex and expensive.
The Fraunhofer Institute for Applied Solid State Physics IAF has therefore developed a semi-automated process ...
In September 2023, a bizarre global seismic signal was observed which appeared every 90 seconds over nine days – and was then repeated a month later. Almost a year later, two scientific studies proposed that the cause of these seismic anomalies were two mega tsunamis which were triggered in a remote East Greenland fjord by two major landslides which occurred due to warming of an unnamed glacier. The waves were thought to have become trapped in the fjord system, forming standing waves (or seiches) that undulated back and forth, causing the mystery signals.
However, ...
EMBARGOED FOR RELEASE UNTIL 5:00 A.M. ET, TUESDAY, JUNE 3, 2025
New mRNA Vaccine is More Effective and Less Costly to Develop, Pitt Study Finds
PITTSBURGH, JUNE 3, 2025 – A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study by researchers at University of Pittsburgh School of Public Health and the Pennsylvania State University. The study was published today in npj Vaccines.
Though highly effective at inducing an immune response, current mRNA vaccines, such as those used to prevent COVID-19, present two significant challenges: the high amount of mRNA needed ...
Dublin is known as a city where you can enjoy a few pints of Guiness, get a warm welcome from the locals and hear lively traditional music drifting out of pubs and into the city air.
But it’s not just music floating on the breeze. The air of Dublin also contains cannabis, poppy, even magic mushrooms — at least their DNA.
That’s according to a new study that reveals the power of DNA, vacuumed up from the air, which can track everything from elusive bobcats to illicit drugs.
“The level of ...
Infections caused by herpes simplex virus type 1 (HSV-1) can lead to HSV-1 encephalitis—a rare but deadly condition that inflames the brain. Despite decades of research, treatment options for this disease remain limited. HSV-1 has evolved alongside human hosts and developed strategies to evade immune responses, particularly in the brain. One key line of defense, the apolipoprotein B mRNA editing enzyme (APOBEC), a catalytic polypeptide-like family of proteins, can introduce mutations into viral DNA to prevent infection. However, HSV-1 is able to bypass this mechanism, ...
Algorithmically-driven social media has split red and blue America into separate information environments. But a new online tool, developed at Harvard, can bring citizens back together.
The virtual quiz game Tango pairs Democrats and Republicans on common teams, where bipartisanship quickly emerges as their competitive superpower. “It’s really the opposite of the nasty, divisive posting you find on social media,” offered Tango co-creator Joshua D. Greene, a professor of psychology and co-author of new study measuring the game’s impact.
The ...
Plants produce an enormous abundance of natural products. Many plant natural products are ancestry-specific and occur only in certain plant families, sometimes only in a single species. Interestingly, however, the same substances can sometimes be found in distantly related species. In most cases, however, only the end product is known and it is largely unclear how these substances are produced in plants. Ipecacuanha alkaloids occur in two distantly related plant species known as medicinal plants: in ipecac Carapichea ipecacuanha, which belongs to the gentian ...
As psychedelics gain traction as potential treatments for mental health disorders, an international study led by researchers at McGill University, Imperial College London, and the University of Exeter stands to improve the rigour and reliability of clinical research.
Up to now, psychedelic clinical trials have had what has been widely acknowledged as a critical flaw: the failure to properly account for how a person’s mindset and surroundings influence the effects of psychedelics such as MDMA and psilocybin. This gap has led to inconsistent study results, making regulatory approval more difficult.
To address this, the researchers ...
EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6.
The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of patients had tumours expressing the antigen at levels considered treatable with EBC-129.
EBC-129 demonstrated positive overall response rates and prolonged progression-free survival in PDAC patients that have been heavily pre-treated, including those ...
A new study in Genome Biology and Evolution, published by Oxford University Press, finds that the African Swine Fever virus, currently circulating in Europe, is not the result of a recent introduction. Instead, the virus has been present in the region since 2007. Its current dramatic spread appears to be driven largely by people within Europe traveling longer distances.
African Swine Fever virus is a highly virulent DNA virus that causes a severe hemorrhagic disease of the same name affecting both domestic pigs and wild boars. The disease is characterized by high mortality rates, leading to significant economic losses in the pork industry. According to estimates ...
